Mast Therapeutics SVRA 深 沪
已收盘 12-12 16:00:00 美东时间
6.92
-0.020
-0.29%
华盛通- 最 高7.005
- 今 开6.98
- 成交量 293.19万股
- 最 低 6.77
- 昨 收 6.94
- 总市值 11.97亿
- 52周最高 7.005
- 市盈率 静 --
- 换手率 1.69%
- 52周最低 1.89
- 委 比 68.70%
- 总股本 1.73亿
- 历史最高 17.187
- 量 比 0.87
- 振 幅 3.39%
- 历史最低 0.69
- 每 手 1
- 风险率 0.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多European Patent Office Intends To Grant Savara Patent For Liquid Formulation Of MOLBREEVI
-- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 ---- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI
12-11 21:16
Savara Inc. ticks higher amid takeover speculation
Savara Inc. (SVRA) pared a loss and ticked higher by 0.2% amid takeover speculation. There's speculation that Savara may have attracted takeover interest, according to traders, who cited a Betaville ...
12-03 03:39
Micron, Endeavour Silver, First Majestic Silver, Applied Digital And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones gaining around 300 points on Friday...
11-29 00:19
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Oppenheimer Maintains Outperform on Savara, Raises Price Target to $9
Oppenheimer analyst Andreas Argyrides maintains Savara (NASDAQ:SVRA) with a Outperform and raises the price target from $8 to $9.
11-15 01:30
Savara Q3 EPS $(0.14) Misses $(0.13) Estimate
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 5.26 percent. This is a 27.27 percent decrease over losses of $(0.11) per share from the same
11-13 05:21
Savara Hit with Class Action Over Molbreevi Misrepresentations
Aclass actionlawsuit was filed againstSavara Inc. ($SVRA) on ...
11-04 14:29
Savara prices $130M equity at $4.20
Clinical stage biopharmaceutical company focused on rare respiratory diseases—Savara (SVRA) priced an underwritten public offering of ~23.81M shares at a price of $4.20 per share. Total gross proceeds...
10-30 15:35
Savara Announces $75M Financing Agreement With RTW Investments
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $75 million royalty funding agreement with funds managed by RTW Investments, LP
10-30 04:03
Savara Presents New Data From Phase 3 IMPALA-2 Showing Molgramostim Beneficial In aPAP Patients Regardless Of Disease Severity
– The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% –– Changes in DLco%, the Primary Endpoint in IMPALA-2, Were Significantly Correlated
09-29 15:22
